Active nutation controller

An apparatus is described for controlling nutation motion in a spinning body, comprised of an angular accelerometer with its input axis perpendicular to the spin axis of the body, a flywheel with an axis of rotation perpendicular to the axis of the accelerometer and to the spin axis of the body, and a motor for driving the flywheel to attenuate or build nutation. The motor is controlled by circuitry that monitors the output of the angular accelerometer and drives the motor clockwise or counterclockwise during predetermined nutation angles synchronized to the zero crossover points of the accelerometer signal centered about the nutation peaks. The motor drive is phased to damp nutation motion to zero for stabilization. To increase the noise immunity of the system, when the output of the accelerometer falls below a threshold level, the circuitry operates in an open loop, beat mode where data representing the last accelerometer signal that exceeded that threshold level is stored, and the motor drive is controlled by the stored data. In a second version, the motor is controlled to supply a predetermined amount of nutation motion to a body undergoing testing on a spin table for energy dissipation evaluation. In each version, the use of an angular accelerometer rather than a linear accelerometer or gyro to monitor nutation enables placement of the nutation control apparatus at any location relative to the spin axis of the body requiring only crude orientation and no calibration

Regression of ranked responses when raw responses are censored

We discuss semiparametric regression when only the ranks of responses are observed. The model is $Y_i = F (\mathbf{x}_i'{\boldsymbol\beta}_0 + \varepsilon_i)$, where $Y_i$ is the unobserved response, $F$ is a monotone increasing function, $\mathbf{x}_i$ is a known $p-$vector of covariates, ${\boldsymbol\beta}_0$ is an unknown $p$-vector of interest, and $\varepsilon_i$ is an error term independent of $\mathbf{x}_i$. We observe $\{(\mathbf{x}_i,R_n(Y_i)) : i = 1,\ldots ,n\}$, where $R_n$ is the ordinal rank function. We explore a novel estimator under Gaussian assumptions. We discuss the literature, apply the method to an Alzheimer's disease biomarker, conduct simulation studies, and prove consistency and asymptotic normality.Comment: 33 pages, 6 figure

Teaching Spoken English at Junior High School: A Comparison of TPR and PPP

This article reports on an experimental methods-comparison study, which was undertaken with beginner level junior high school students (aged 12 and 13) in Japan. The study aimed to investigate which type of teaching, Total Physical Response (TPR) or Present Practice Produce (PPP), was more effective in developing productive and receptive knowledge of a set of collocations. Results showed that both types of teaching had a significant impact upon the development of understanding and using the target language. However, there were no significant differences between the effectiveness of TPR and PPP, apart from a short-term benefit for PPP in terms of receptive knowledge. This shows that both types of teaching can have a positive impact upon learners of this age and level and that there is a need for further research to investigate the effectiveness of these communicative methodologies in this context

Joseph Donohue, Senior Art Exhibition Portfolio

Senior art exhibition for the semester of Spring 2019, shown in the Godschalx Gallery from April 8th to May 3rd. Two sculptural pieces and a photography piece are shown of my work.https://digitalcommons.snc.edu/artportfolios/1032/thumbnail.jp

Neuroanatomical spread of amyloid β and tau in Alzheimer's disease: implications for primary prevention.

With recent advances in our understanding of the continuous pathophysiological changes that begin many years prior to symptom onset, it is now apparent that Alzheimer's disease cannot be adequately described by discrete clinical stages, but should also incorporate the continuum of biological changes that precede and underlie the clinical representation of the disease. By jointly considering longitudinal changes of all available biomarkers and clinical assessments, variation within individuals can be integrated into a single continuous measure of disease progression and used to identify the earliest pathophysiological changes. Disease time, a measure of disease severity, was estimated using a Bayesian latent time joint mixed-effects model applied to an array of imaging, biomarker and neuropsychological data. Trajectories of regional amyloid β and tau PET uptake were estimated as a function of disease time. Regions with early signs of elevated amyloid β uptake were used to form an early, focal composite and compared to a commonly used global composite, in a separate validation sample. Disease time was estimated in 279 participants (183 cognitively unimpaired individuals, 61 mild cognitive impairment and 35 Alzheimer's disease dementia patients) with available amyloid β and tau PET data. Amyloid β PET uptake levels in the posterior cingulate and precuneus start high and immediately increase with small increases of disease time. Early elevation in tau PET uptake was found in the inferior temporal lobe, amygdala, banks of the superior temporal sulcus, entorhinal cortex, middle temporal lobe, inferior parietal lobe and the fusiform gyrus. In a separate validation sample of 188 cognitively unimpaired individuals, the early, focal amyloid β PET composite showed a 120% increase in the accumulation rate of amyloid β compared to the global composite (P < 0.001), resulting in a 60% increase in the power to detect a treatment effect in a primary prevention trial design. Ordering participants on a continuous disease time scale facilitates the inspection of the earliest signs of amyloid β and tau pathology. To detect early changes in amyloid β pathology, focusing on the earliest sites of amyloid β accumulation results in more powerful and efficient study designs in early Alzheimer's disease. Targeted composites could be used to re-examine the thresholds for amyloid β-related study inclusion, especially as the field shifts to focus on primary and secondary prevention. Clinical trials of anti-amyloid β treatments may benefit from the use of focal composites when estimating drug effects on amyloid β and tau changes in populations with minimal amyloid β and tau pathology and limited expected short-term accumulation